Print Page  Close Window

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
01/29/18Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
Data Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections in Immunocompromised Patients SAN DIEGO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its lead antifungal candidate rezafungin acetate, formerly known as CD101 IV, will be presented at two upcoming medical co... 
01/04/18Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of papers published as a Journal of Antimicrobial Chemotherapy supplement reviews evidence and provides insights into the future of echinocandin therapy, including strategies for the t...